Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by 95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease.

This secondary analysis of the OCEAN(a)-DOSE randomized clinical trial investigates the effect of the small-interfering RNA olpasiran on atherogenic lipoproteins.